Jul. 18 at 4:24 PM
$MESO Mesoblast’s Ryoncil® (remestemcel-L) commercial launch recap:
First & only FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease
$13.2M in Q2 gross sales (Mar 28–Jun 30)
$1.6M in royalties from TEMCELL® sales in Japan 🇯🇵
Now covered by Medicare/Medicaid
7-year orphan drug exclusivity + 12-year BLA protection
25 US transplant centers onboarded, targeting 45 🏥
#Biotech #CellTherapy